UBS Group upgraded shares of Evommune (NYSE:EVMN – Free Report) to a hold rating in a report published on Sunday,Zacks reports.
Other analysts also recently issued reports about the stock. Royal Bank Of Canada reduced their target price on shares of Evommune from $29.00 to $21.00 and set an “outperform” rating on the stock in a report on Wednesday, September 9th. Morgan Stanley dropped their target price on Evommune from $55.00 to $26.00 and set an “overweight” rating on the stock in a research report on Tuesday, June 30th. Wall Street Zen downgraded shares of Evommune from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Leerink Partners lowered their price target on shares of Evommune from $28.00 to $22.00 and set an “outperform” rating on the stock in a report on Wednesday, September 9th. Finally, Stifel Nicolaus set a $30.00 price target on shares of Evommune in a research report on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $30.80.
View Our Latest Report on EVMN
Evommune Price Performance
Evommune (NYSE:EVMN – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.21). As a group, sell-side analysts expect that Evommune will post -3.29 EPS for the current fiscal year.
Institutional Trading of Evommune
Institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC purchased a new stake in Evommune during the 2nd quarter valued at approximately $634,000. Velan Capital Investment Management LP grew its position in Evommune by 1.1% during the second quarter. Velan Capital Investment Management LP now owns 451,255 shares of the company’s stock worth $5,997,000 after buying an additional 5,000 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of Evommune in the 2nd quarter worth approximately $340,000. Defilade Capital Management L.P. increased its position in shares of Evommune by 215.0% in the first quarter. Defilade Capital Management L.P. now owns 678,589 shares of the company’s stock valued at $15,601,000 after buying an additional 463,171 shares in the last quarter. Finally, Perceptive Advisors LLC acquired a new position in Evommune during the first quarter worth about $10,308,000.
About Evommune
Evommune, Inc is a clinical-stage biotechnology company focused on developing new treatments for immune-mediated inflammatory diseases. The company’s research is centered on identifying therapies that address the underlying biological mechanisms driving chronic inflammation rather than primarily treating symptoms.
Evommune is advancing a pipeline of investigational medicines designed for conditions with significant unmet medical needs, including dermatologic and other inflammatory disorders.
Recommended Stories
- Five stocks we like better than Evommune
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
Receive News & Ratings for Evommune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evommune and related companies with MarketBeat.com's FREE daily email newsletter.
